CCA
ALNY icon

Column Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Column Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3
Closed -$1K – 716
2021
Q4 		$1K Buy
+3
New +$558 ﹤0.01% 690
2021
Q2 		– Sell
-100
Closed -$14K – 719
2021
Q1 		$14K Hold
100
– – ﹤0.01% 410
2020
Q4 		$13K Hold
100
– – ﹤0.01% 421
2020
Q3 		$15K Hold
100
– – ﹤0.01% 388
2020
Q2 		$14K Hold
100
– – ﹤0.01% 420
2020
Q1 		$11K Sell
100
-43
-30% -$4.96K ﹤0.01% 371
2019
Q4 		$16K Buy
+143
New +$14.3K 0.01% 395

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Column Capital Advisors's ALNY Position: Q1 2022 in Review

Column Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 3 shares — an estimated $1K sold.

Column Capital Advisors first reported a position in ALNY in Q4 2019 and held it in 7 quarters. The position peaked at $16K in Q4 2019. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • Column Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Column Capital Advisors sold 3 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $1K.
  • Column Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Column Capital Advisors's Alnylam Pharmaceuticals position peaked at $16K in Q4 2019.
  • 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Column Capital Advisors's 13F filing for Q1 2022, filed 3 May 2022.